A coalition taxpayer and consumer groups sent a letter to Illinois House members explaining that H.B. 4900 — the Illinois Generic Drug Pricing Fairness Act — would seek to target generic drug pricing and impede generic competition, while leaving more expensive name brand drugs unaffected. While working families, small businesses, seniors, and especially society’s most vulnerable patients are feeling the brunt of rising prescription drug costs, a “solution” that only targets generic pharmaceutical manufacturers jeopardizes the very industry that is a key to holding down drug prices. The Illinois General Assembly would be better served promoting policies that encourage drug competition, instead of protecting the high costs of originator brand drugs.
To read the coalition letter, click here.